The term coryneform refers to pleomorphic gram-positive bacilli that are arranged in an angular formation and that may appear coccoid under certain growth conditions. Organisms of coryneform groups A through I differ from those of the genus Corynebacterium in that the cell walls of the latter contain meso-diaminopimelic acid, arabinose, galactose, and relatively short-chain mycolic acids (2) . Hollis and Weaver (5) described the biochemical and physiological properties of several coryneform group A isolates, which were then referred to as group A Corynebacterium species. Their collection of group A-4 coryneforms included 40 strains isolated from a variety of sources, including cerebrospinal fluid, blood, urine, and pleural fluid. In general, members of this group produced catalase, actively fermented carbohydrates, hydrolyzed esculin but not urea, and seldom reduced nitrate. To date, the Special Bacterial Pathogens Laboratory (Division of Bacterial Diseases, Centers for Disease Control [CDC] , Atlanta, Ga) has received approximately 85 group A-4 isolates and 15 additional isolates that are similar to group A-4; all were isolated from clinical specimens (D. G.
Hollis, personal communication).
One case of endophthalmitis caused by a coryneform group A-4 strain has been reported by Hanscom and Maxwell (3). The organism was isolated from the vitreous humor of a patient who sustained an intraocular, metallic, foreign body injury. The foreign body was removed, and the patient was treated intravitreously and intravenously with gentamicin and methicillin. Functional vision was restored.
We report here the isolation and characterization of two strains of an unusual gram-positive organism that is similar to coryneform group A-4. The strains were isolated from the vitreouses of two patients who presented with delayed endophthalmitis after intraocular lens implantation. The results of in vitro susceptibility testing are also reported. * Corresponding author.
MATERIALS AND METHODS
Source of organisms. Vitreous fluid from each of two patients examined on separate occasions was inoculated directly onto 5% sheep blood agar and supplemented chocolate agar and into brain heart infusion broth supplemented with 10% horse serum. The media were transported to the clinical microbiology laboratory and were incubated at 37°C. In addition to clinical isolates, five reference strains of coryneform group A-4 and five atypical strains, referred to as A-4-like strains, were provided by R. E. Weaver and D. G. Hollis of the Special Bacterial Pathogens Laboratory, CDC.
Biochemical tests. All fermentation tests were performed with a purple broth base with 1% (wt/vol) sugar (8) . Unless indicated otherwise, all media and reagents were obtained from Difco Laboratories, Detroit, Mich. Nitrate reduction was determined with a commercially available nitrate broth. Gelatin and esculin broth media contained 0.4% gelatin and 0.1% esculin (wt/vol), respectively. The esculin medium was prepared as described previously (8) , with the exception of 1.0% peptone and 0.5% NaCl replacing the heart infusion agar. Colony pigmentation was determined from growth on blood agar plates after 4 days of incubation at 37°C.
For gas chromatographic analyses of acid metabolic products, organisms were inoculated into 2.8 ml of prereduced anaerobically sterilized PY glucose (Carr-Scarborough Microbiologicals, Decatur, Ga.), and grown under aerobic conditions at 37°C. After 24 to 48 h, cultures were visibly turbid (McFarland no. 1). Acidification of the cultures and extraction of the volatile and nonvolatile products were performed as described by Holdeman et al. (4) . Samples were analyzed with a Hewlett-Packard 5880A gas chromatograph (Hewlett-Packard Co., Avondale, Pa.) equipped with a stainless steel column containing SP-1000/H3PO4 coated on 100/120 Chromosorb W. Retention times of known acids in a Table 1 also shows the acid metabolic products of all strains tested. Only A-4 strains produced lactic acid, but two of them (D640 and C8759) produced small amounts. Also, clinical and A-4-like strains produced relatively more succinic acid than did A-4 strains; for example, A-4-like strain F4277 produced 2.9-fold more succinic acid than did A-4 strain C6391, based on percent area of each succinic peak relative to the area of the same peak of the known standard.
Results of in vitro susceptibility tests are shown in Table  2 . The MIC and MBC of each antibiotic for both clinical strains were within 1 log2 dilution. The MBC of cefazolin was 7 tube dilutions above the MIC for each isolate. In addition to biochemical characteristics, the acid metabolic products of the 12 strains tested also suggest that the A-4-like strains may represent a new group or a subgroup of the coryneform A-4 group. Only A-4 strains produced lactic acid. The fact that two of these strains produced small amounts of lactic acid also emphasizes the need to study additional strains.
Not only did the two clinical isolates appear similar biochemically, but susceptibility test results of three antibiotics for both isolates were nearly identical. For therapeutic reasons it is important to recognize the apparent discrepancies between the MIC and MBC endpoints for each organism. Such discrepancies were more evident with cefazolin and gentamicin, which are the drugs most frequently used to treat patients with bacterial endophthalmitis. Clinically, both patients received subconjunctival injections of gentamicin prophylactically after implantation of the lenses and later received oral penicillin. Functional vision was restored in both instances.
In summary, we isolated two A-4-like strains from the vitreous fluid of two patients with endophthalmitis. Biochemical and gas chromatographic patterns suggest that these strains may represent a subgroup of coryneform group A-4. Susceptibility studies emphasize the importance of determining MBCs for slow-growing organisms. This report encourages microbiologists to use good judgment when working up organisms isolated from body fluids that are normally sterile and from patients receiving localized steroid therapy.
